Analysts have been mostly positive on the uptake, and a report noted that Zulresso’s risk evaluation and mitigation strategies (REMS) requirement for continuous 60-hour assessment might complicate uptake, but it should be easily overcome as such monitoring is common practice.
However, experts said it will not be issues with REMS that impedes uptake, but the fact that many mothers might be unable to find support to care for their infants while admitted.
REMS is a drug safety programme that the US Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.